Bristol-Myers Squibb Joins Multiple Myeloma Research Foundation (MMRF) to Advance Personalized Medicine Approaches for Multiple

  Bristol-Myers Squibb Joins Multiple Myeloma Research Foundation (MMRF) to
  Advance Personalized Medicine Approaches for Multiple Myeloma

  Innovative Pre-competitive Consortium is Focused on Translating Scientific
 Findings from Landmark Multiple Myeloma Study into Therapeutic Advances for
                                   Patients

Business Wire

NORWALK, Conn. -- December 14, 2012

The Multiple Myeloma Research Foundation (MMRF) today announced that
Bristol-Myers Squibb has joined the MMRF pre-competitive consortium (PCC) to
discover and accelerate new approaches to treating multiple myeloma through
the organization’s Personalized Medicine Initiative (PMI).

The cornerstone of the PMI is the landmark MMRF CoMMpass℠ Study
(RelatingClinical Outcomes inMultiple Myelomato PersonalAssessment of
Genetic Profile), which will follow 1,000 newly diagnosed multiple myeloma
patients over five years to understand the molecular changes underpinning the
progression of the disease. The study, which opened to enrollment in July
2011, has 50 active sites that have screened more than 200 patients to date.

“Multiple myeloma is the second most common blood cancer and there remains a
high unmet medical need for these patients,” said Joe Leveque, M.D., Vice
President of U.S. Oncology Medical Strategy at Bristol-Myers Squibb. “We are
pleased to join with the MMRF on this collaborative approach to research,
which highlights Bristol-Myers Squibb’s commitment to seeking advances in care
for patients with hematological malignancies. It also underscores our
commitment to incorporating personalized medicine approaches into the drug
development process for oncology, including multiple myeloma, as a way to
improve patient outcomes.”

Members of the PCC, including Bristol-Myers Squibb, Millennium: The Takeda
Oncology Company, Onyx Pharmaceuticals, Inc., and several academic and
non-profit entities, provide scientific and financial support for the PMI.
This innovative, collaborative and diverse partnership structure provides
researchers access to the findings from the PMI, including CoMMpass, to
identify and advance personalized treatment approaches at an accelerated pace.

“Our partnership with Bristol-Myers Squibb is a vital component of the PMI, as
it signifies the growing interest among the industry’s oncology leaders to
drive scientific and clinical innovation through new models of collaboration,”
stated Walter M. Capone, Chief Operating Officer of the MMRF and the Multiple
Myeloma Research Consortium (MMRC). “We applaud Bristol-Myers Squibb and all
of the members of the PCC for their vision, commitment, and support of our
mission to accelerate the translation of research findings into therapeutic
advancements for patients. We look forward to working closely with the
Bristol-Myers Squibb team to deliver personalized approaches to even more
effectively treat this difficult disease.”

About Multiple Myeloma

Multiple myeloma is an incurable blood cancer. The five-year relative survival
rate for multiple myeloma is approximately 38 percent, one of the lowest of
all cancers. In 2012, more than 20,000 adults in the United States will be
diagnosed with multiple myeloma and nearly 11,000 people are predicted to die
from the disease.

About the Multiple Myeloma Research Foundation (MMRF)

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a
501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy
Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the
MMRF is to relentlessly pursue innovative means that accelerate the
development of next-generation multiple myeloma treatments to extend the lives
of patients and lead to a cure. As the world's number-one private funder of
multiple myeloma research, the MMRF has raised over $200 million since its
inception and directs 90% of total budget to research and related programming.
As a result, the MMRF has been awarded Charity Navigator’s coveted four
four-star rating for nine consecutive years, the highest designation for
outstanding fiscal responsibility and exceptional efficiency. For more
information about the MMRF, please visit www.themmrf.org.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to
discover, develop and deliver innovative medicines that help patients prevail
over serious diseases. For more information, please visit www.bms.com or
follow us on Twitter at http://twitter.com/bmsnews.

Contact:

MMRF
Anne Quinn Young, 203-536-8691
QuinnYoungA@themmrf.org
 
Press spacebar to pause and continue. Press esc to stop.